Zobrazeno 1 - 10
of 855
pro vyhledávání: '"Brase, C."'
Autor:
Brase C; Translational Medicine, Bayer AG, Wuppertal, Germany., Schmitz S; Statistics, Bayer AG, Berlin, Germany., Sommer K; Biostatistics, ClinStat GmbH, Huerth, Germany., Halabi A; CRS Clinical Research Services, Kiel, Germany., Kanefendt F; Clinical Pharmacology, Bayer AG, Aprather Weg 18a, 42113, Wuppertal, Germany. friederike.kanefendt@bayer.com.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2024 Nov; Vol. 63 (11), pp. 1631-1648. Date of Electronic Publication: 2024 Nov 07.
Autor:
Chen H; Research & Development, Pharmaceuticals, Bayer AG, Beijing, China., Hashizume K; Research & Development Japan, Bayer Yakuhin, Ltd., Tokyo, Japan., Kanefendt F; Research & Development, Pharmaceuticals, Bayer AG, Wuppertal/Leverkusen, Germany., Brase C; Research & Development, Pharmaceuticals, Bayer AG, Wuppertal/Leverkusen, Germany., Schmitz S; Research & Development, Pharmaceuticals, Bayer AG, Berlin, Germany., Liu T; Research & Development, Pharmaceuticals, Bayer AG, Beijing, China.
Publikováno v:
Clinical and translational science [Clin Transl Sci] 2024 Aug; Vol. 17 (8), pp. e13895.
Autor:
Kanefendt F; Research and Early Development, Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Brase C; Research and Early Development, Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Jungmann N; Research and Early Development, DMPK, Bayer AG, Wuppertal, Germany., Fricke R; Research and Early Development, DMPK, Bayer AG, Wuppertal, Germany., Engelen A; Research and Early Development, DMPK, Bayer AG, Wuppertal, Germany., Schmitz S; Research and Early Development, Statistics, Bayer AG, Berlin, Germany.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Apr; Vol. 90 (4), pp. 1036-1049. Date of Electronic Publication: 2024 Jan 09.
Autor:
Brase C; Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Kanefendt F; Clinical Pharmacology, Bayer AG, Wuppertal, Germany., Loewen S; Chrestos Concept GmbH & Co. KG, Essen, Germany., Himmel H; Research & Development, Pharmaceuticals Safety Pharmacology, Bayer AG, Wuppertal, Germany., Schmitz S; Research and Early Development, Statistics, Bayer AG, Wuppertal, Germany.
Publikováno v:
Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2024 Mar; Vol. 13 (3), pp. 265-280. Date of Electronic Publication: 2024 Jan 15.
Autor:
Kanefendt F; Clinical Pharmacology, Bayer AG, Berlin, Germany., Dallmann A; Bayer HealthCare SAS, Loos, France, on behalf of Bayer AG, Pharmacometrics/Modeling and Simulation, Systems Pharmacology & Medicine - PBPK, Germany., Chen H; Clinical Pharmacology Asia, Bayer AG, China., Francke K; Translational Medicine, Bayer AG, Germany., Liu T; Clinical Pharmacology Asia, Bayer AG, China., Brase C; Translational Medicine, Bayer AG, Germany., Frechen S; Systems Pharmacology & Medicine - PBPK, Bayer AG, Germany., Schultze-Mosgau MH; Clinical Pharmacology, Bayer AG, Berlin, Germany.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2024 May; Vol. 115 (5), pp. 1025-1032. Date of Electronic Publication: 2024 Jan 08.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Physics Letters
We calculate the nuclear matrix element for the two-neutrino ββ decay of $^{136}$Xe into the first excited 0+ state of $^{136}$Ba. We use different many-body methods: the quasiparticle random-phase approximation (QRPA) framework, the nuclear shell
We calculate the nuclear matrix element for the two-neutrino $\beta\beta$ decay of $^{136}$Xe into the first excited $0^+$ state of $^{136}$Ba. We use different many-body methods: the quasiparticle random-phase approximation (QRPA) framework, the nuc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d0abe51f897820a988c5ed29fb893c8
http://urn.fi/URN:NBN:fi:jyu-202301191392
http://urn.fi/URN:NBN:fi:jyu-202301191392
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Piel I; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Engelen A; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Lang D; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Schulz SI; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Gerisch M; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Brase C; Clinical Pharmacology, Bayer AG, 42096, Wuppertal, Germany., Janssen W; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Fiebig L; Drug Metabolism and Pharmacokinetics, Bayer AG, Wuppertal, Germany., Heitmeier S; Preclinical Pharmacology, Bayer AG, Wuppertal, Germany., Kanefendt F; Clinical Pharmacology, Bayer AG, 42096, Wuppertal, Germany. friederike.kanefendt@bayer.com.
Publikováno v:
European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2023 Jul; Vol. 48 (4), pp. 411-425. Date of Electronic Publication: 2023 Jun 26.